Metabolic Meds Startup Verdiva Launches With $411M and a Weekly Oral GLP-1 Drug

January 9, 2025
, 9:00 pm

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Verdiva Bio’s once-a-week oral GLP-1 drug is ready for Phase 2 testing. The drug, made with a proprietary technology that enables oral dosing, was licensed from Sciwind Biosciences.

The post Metabolic Meds Startup Verdiva Launches With $411M and a Weekly Oral GLP-1 Drug appeared first on MedCity News.

Leave a Replay

HHS’ Proposed HIPAA Changes Are a Step in the Right Direction, But Some Providers May Struggle to Comply

When Algorithms Decide Who Lives and Who Suffers

Morgan Health: 5 Ways AI Can Improve Employer-Sponsored Healthcare

Sign up for our Newsletter

HealthGility provides healthcare organizations with a solution for patient protected health information disclosure and confidentiality that reduces workloads and ensures the safe and secure sharing of sensitive data between different providers.

Metabolic Meds Startup Verdiva Launches With $411M and a Weekly Oral GLP-1 Drug

Leave a Replay

Related Posts

HHS’ Proposed HIPAA Changes Are a Step in the Right Direction, But Some Providers May Struggle to Comply

When Algorithms Decide Who Lives and Who Suffers

Morgan Health: 5 Ways AI Can Improve Employer-Sponsored Healthcare

Follow Us

Sign up for our Newsletter

Our Company

Resources

Connect

© All rights reserved

Contact Us